Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMMP NASDAQ:QURE NASDAQ:UPB NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMPPrima BioMed$1.62-0.6%$1.70$1.32▼$2.72$239.26M1.7170,464 shs143,439 shsQUREuniQure$17.73+2.0%$14.90$4.45▼$19.18$953.59M0.14817,239 shs976,912 shsUPBUpstream Bio$19.68-1.6%$14.62$5.14▼$29.46$1.08BN/A528,468 shs563,563 shsURGNUrogen Pharma$18.80-2.9%$17.43$3.42▼$21.01$896.14M1.1980,269 shs1.89 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMPPrima BioMed-0.61%-2.41%-8.99%-12.90%-35.97%QUREuniQure+2.01%+9.04%+26.64%+2.66%+227.73%UPBUpstream Bio-1.60%+17.42%+26.97%+74.62%+1,967,999,900.00%URGNUrogen Pharma-2.94%-2.29%-9.27%+155.09%+34.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMPPrima BioMed$1.62-0.6%$1.70$1.32▼$2.72$239.26M1.7170,464 shs143,439 shsQUREuniQure$17.73+2.0%$14.90$4.45▼$19.18$953.59M0.14817,239 shs976,912 shsUPBUpstream Bio$19.68-1.6%$14.62$5.14▼$29.46$1.08BN/A528,468 shs563,563 shsURGNUrogen Pharma$18.80-2.9%$17.43$3.42▼$21.01$896.14M1.1980,269 shs1.89 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMPPrima BioMed-0.61%-2.41%-8.99%-12.90%-35.97%QUREuniQure+2.01%+9.04%+26.64%+2.66%+227.73%UPBUpstream Bio-1.60%+17.42%+26.97%+74.62%+1,967,999,900.00%URGNUrogen Pharma-2.94%-2.29%-9.27%+155.09%+34.57%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMMPPrima BioMed$5.14M46.26N/AN/A$1.05 per share1.54QUREuniQure$27.12M35.87N/AN/A($0.14) per share-126.64UPBUpstream Bio$2.37M447.66N/AN/A$8.77 per share2.24URGNUrogen Pharma$90.40M9.62N/AN/A($0.21) per share-89.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMMPPrima BioMed-$39.78MN/A0.00N/AN/AN/AN/AN/AN/AQUREuniQure-$239.56M-$3.92N/AN/AN/A-1,387.98%-1,010.74%-33.27%11/4/2025 (Estimated)UPBUpstream Bio-$62.81MN/A0.00N/AN/A-3,836.58%-35.90%-26.26%11/6/2025 (Estimated)URGNUrogen Pharma-$126.87M-$3.32N/AN/AN/A-164.44%-97,487.15%-59.38%11/5/2025 (Estimated)Latest IMMP, UPB, URGN, and QURE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025URGNUrogen Pharma-$0.82-$1.05-$0.23-$1.05$23.06 million$24.22 million8/6/2025Q2 2025UPBUpstream Bio-$0.61-$0.74-$0.13-$0.74$0.32 million$0.94 million7/29/2025Q2 2025QUREuniQure-$0.89-$0.69+$0.20-$0.69$5.00 million$5.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMMPPrima BioMedN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMMPPrima BioMedN/A18.86N/AQUREuniQure1.539.989.98UPBUpstream BioN/A38.2738.27URGNUrogen PharmaN/A4.143.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMMPPrima BioMed2.32%QUREuniQure78.83%UPBUpstream BioN/AURGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipIMMPPrima BioMed3.07%QUREuniQure4.79%UPBUpstream Bio13.56%URGNUrogen Pharma4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMMPPrima BioMed2,021146.79 million142.28 millionOptionableQUREuniQure50054.87 million52.24 millionOptionableUPBUpstream Bio3853.91 million46.60 millionN/AURGNUrogen Pharma20046.26 million44.09 millionOptionableIMMP, UPB, URGN, and QURE HeadlinesRecent News About These CompaniesVestal Point Capital LP Boosts Position in Urogen Pharma $URGNSeptember 4 at 7:17 AM | marketbeat.comRA Capital Management L.P. Acquires Shares of 3,206,271 Urogen Pharma $URGNSeptember 4 at 7:02 AM | marketbeat.comNuveen LLC Invests $1.03 Million in Urogen Pharma $URGNSeptember 3 at 3:38 AM | marketbeat.comPartners Capital Investment Group LLP Invests $170,000 in Urogen Pharma $URGNAugust 24, 2025 | marketbeat.comUroGen Pharma to Present at Upcoming Investor ConferencesAugust 21, 2025 | globenewswire.comFox Run Management L.L.C. Takes Position in Urogen Pharma $URGNAugust 21, 2025 | marketbeat.comPiper Sandler Initiates Coverage of UroGen Pharma (URGN) with Overweight RecommendationAugust 20, 2025 | msn.comPiper starts ‘underestimated’ UroGen Pharma with an OverweightAugust 19, 2025 | msn.comUroGen Pharma initiated with an Overweight at Piper SandlerAugust 18, 2025 | msn.comUroGen Pharma: Targeting Profits In 2027August 18, 2025 | seekingalpha.comOak Ridge Investments LLC Has $815,000 Position in Urogen Pharma (NASDAQ:URGN)August 17, 2025 | marketbeat.comQ3 EPS Estimates for Urogen Pharma Reduced by HC WainwrightAugust 16, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 SharesAugust 15, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 14, 2025 | marketbeat.com17,571 Shares in Urogen Pharma (NASDAQ:URGN) Acquired by Persistent Asset Partners LtdAugust 13, 2025 | marketbeat.comUroGen Pharma’s Earnings Call: Achievements and ChallengesAugust 13, 2025 | msn.comUroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comHC Wainwright Issues Pessimistic Forecast for Urogen Pharma (NASDAQ:URGN) Stock PriceAugust 12, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Releases Earnings Results, Misses Expectations By $0.20 EPSAugust 11, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their EstimatesAugust 10, 2025 | finance.yahoo.comUroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMMP, UPB, URGN, and QURE Company DescriptionsPrima BioMed NASDAQ:IMMP$1.62 -0.01 (-0.61%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$1.58 -0.05 (-2.78%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.uniQure NASDAQ:QURE$17.73 +0.35 (+2.01%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$17.60 -0.13 (-0.73%) As of 05:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Upstream Bio NASDAQ:UPB$19.68 -0.32 (-1.60%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$19.66 -0.02 (-0.13%) As of 09/4/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.Urogen Pharma NASDAQ:URGN$18.80 -0.57 (-2.94%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$18.82 +0.02 (+0.08%) As of 09/4/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
